17 of the world’s leading pharmas rely on our preclinical models to produce clinically translatable data

‍

Our models help researchers unlock valuable insights to move forward in their preclinical studies and publish in high-impact scientific journals; here are a few examples:

Model used: genO-panhCD3

Poster: AZD5863, a CLDN18.2 and CD3 binding T-cell engager, establishes a multi-faceted antitumour immune response and combines effectively with chemo-immunotherapy regimens

Conference: SITC 2024

Key application of the model: Tested the efficacy of a next-generation T cell engager that balances efficacy and safety for targeting CLDN18.2-expressing cancers

Model used: genO-hVISTA

Publication: VISTA is an acidic pH-selective ligand for PSGL-1

Journal: Nature

Key application of the model: Identified VISTA as an acidic pH-selective ligand for PSGL-1, which interaction suppresses T cell activation

Model used: genO-hSA/hFcRn

Publication: In Vivo Half-Life Extension of BMP1/TLL Metalloproteinase Inhibitors Using Small-Molecule Human Serum Albumin Binders

Journal: Bioconjugate Chemistry

Key application of the model: Conducted PK profiling of therapeutics with extended half-life

Model used: genO-hCD3ε

Publication: A Novel B7-H4xCD3 Bispecific T Cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune-Checkpoint Therapies

Journal: Molecular Cancer Therapeutics

Key application of the model: Assessed the efficacy of a bispecific antibody which redirects T cells to kill B7-H4+ breast cancer cells

Model used: genO-BRGSF-HIS

Poster: Preclinical in vivo characterization of the anti-tumor activity of a non-blocking PD-1 antibody fused to attenuated IL-2

Conference: SITC 2024

Key application of the model: Analyzed the efficacy of their anti-PD-1-IL-2 construct

Model used: genO-hPD-1/hGITR/hGITRL

Publication: An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy

Journal: Nature Cancer

Key application of the model: Tested the T-cell activation and tumor growth inhibition of a anti-PD-1–GITR-L bispecific agonist through optimized GITR clustering

‍